Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $41

Benzinga · 3d ago
Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $48 to $41.